Arthur m. Krieg
#96,685
Most Influential Person Now
Arthur m. Krieg's AcademicInfluence.com Rankings
Arthur m. Kriegbiology Degrees
Biology
#4637
World Rank
#6894
Historical Rank
Immunology
#204
World Rank
#213
Historical Rank

Download Badge
Biology
Arthur m. Krieg's Degrees
- Doctorate Medicine University of Iowa
- PhD Immunology University of Iowa
Why Is Arthur m. Krieg Influential?
(Suggest an Edit or Addition)Arthur m. Krieg's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- CpG motifs in bacterial DNA trigger direct B-cell activation (1995) (3654)
- CpG motifs in bacterial DNA and their immune effects. (2002) (2640)
- CpG motifs present in bacteria DNA rapidly induce lymphocytes to secrete interleukin 6, interleukin 12, and interferon gamma. (1996) (1532)
- Therapeutic potential of Toll-like receptor 9 activation (2006) (1195)
- CpG Oligodeoxynucleotides Act as Adjuvants that Switch on T Helper 1 (Th1) Immunity (1997) (1067)
- Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848 (2002) (1028)
- Identification of CpG oligonucleotide sequences with high induction of IFN‐α/β in plasmacytoid dendritic cells (2001) (862)
- Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA. (1996) (824)
- CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. (1998) (722)
- CpG DNA: a potent signal for growth, activation, and maturation of human dendritic cells. (1999) (695)
- Human Plasmacytoid Dendritic Cells Activated by CpG Oligodeoxynucleotides Induce the Generation of CD4+CD25+ Regulatory T Cells1 (2004) (668)
- Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909. (2005) (653)
- Mechanism and Function of a Newly Identified CpG DNA Motif in Human Primary B Cells1 (2000) (647)
- Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. (2001) (630)
- Delineation of a CpG Phosphorothioate Oligodeoxynucleotide for Activating Primate Immune Responses In Vitro and In Vivo1 (2000) (627)
- Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities (2004) (582)
- Immunostimulatory oligodeoxynucleotides containing the CpG motif are effective as immune adjuvants in tumor antigen immunization. (1997) (569)
- Activation of cutaneous dendritic cells by CpG-containing oligodeoxynucleotides: a role for dendritic cells in the augmentation of Th1 responses by immunostimulatory DNA. (1998) (567)
- Cutting Edge: Modulation of Airway Inflammation by CpG Oligodeoxynucleotides in a Murine Model of Asthma (1998) (548)
- Immune stimulation mediated by autoantigen binding sites within small nuclear RNAs involves Toll-like receptors 7 and 8 (2005) (546)
- Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. (2009) (505)
- Bacterial DNA induces NK cells to produce IFN-gamma in vivo and increases the toxicity of lipopolysaccharides. (1996) (453)
- CpG DNA induces sustained IL-12 expression in vivo and resistance to Listeria monocytogenes challenge. (1998) (448)
- Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. (1998) (431)
- Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. (2001) (426)
- Toll‐like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL‐12 (2001) (416)
- Development of TLR9 agonists for cancer therapy. (2007) (398)
- Toll-like receptor 9 (TLR9) agonists in the treatment of cancer (2008) (373)
- The role of CpG motifs in innate immunity. (2000) (373)
- CpG DNA can induce strong Th1 humoral and cell-mediated immune responses against hepatitis B surface antigen in young mice. (1998) (358)
- CpG motifs in bacterial DNA activate leukocytes through the pH-dependent generation of reactive oxygen species. (1998) (352)
- Toll‐like receptors 7, 8, and 9: linking innate immunity to autoimmunity (2007) (342)
- CpG DNA, a novel immune enhancer for systemic and mucosal immunization with influenza virus. (1998) (329)
- Rapid immune activation by CpG motifs in bacterial DNA. Systemic induction of IL-6 transcription through an antioxidant-sensitive pathway. (1996) (323)
- Cancer and Inflammation: Promise for Biologic Therapy (2010) (319)
- Bacterial DNA-Induced NK Cell IFN-γ Production Is Dependent on Macrophage Secretion of IL-12 (1997) (306)
- CpG motifs: the active ingredient in bacterial extracts? (2003) (301)
- Modulation of airway inflammation by CpG oligodeoxynucleotides in a murine model of asthma. (1998) (293)
- Malaria Blood Stage Parasites Activate Human Plasmacytoid Dendritic Cells and Murine Dendritic Cells through a Toll-Like Receptor 9-Dependent Pathway1 (2004) (293)
- CpG motifs in bacterial DNA cause inflammation in the lower respiratory tract. (1997) (284)
- Divergent Therapeutic and Immunologic Effects of Oligodeoxynucleotides with Distinct CpG Motifs1 (2001) (275)
- The role of CpG dinucleotides in DNA vaccines. (1998) (268)
- CpG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry. (1998) (256)
- Identification of RNA Sequence Motifs Stimulating Sequence-Specific TLR8-Dependent Immune Responses1 (2008) (255)
- Immunostimulatory oligodeoxynucleotides promote protective immunity and provide systemic therapy for leishmaniasis via IL-12- and IFN-gamma-dependent mechanisms. (1999) (253)
- Safety and immunogenicity of CPG 7909 injection as an adjuvant to Fluarix influenza vaccine. (2004) (251)
- Rapid induction of mitogen-activated protein kinases by immune stimulatory CpG DNA. (1998) (248)
- CpG motif identification for veterinary and laboratory species demonstrates that sequence recognition is highly conserved. (2001) (248)
- FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga (2017) (247)
- Comparison of cellular binding and uptake of antisense phosphodiester, phosphorothioate, and mixed phosphorothioate and methylphosphonate oligonucleotides. (1993) (230)
- Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides (2004) (217)
- IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. (1996) (215)
- Immunostimulatory oligodeoxynucleotides containing CpG motifs enhance the efficacy of monoclonal antibody therapy of lymphoma. (1997) (214)
- Problems in interpretation of data derived from in vitro and in vivo use of antisense oligodeoxynucleotides. (1994) (212)
- CpG DNA overcomes hyporesponsiveness to hepatitis B vaccine in orangutans. (2000) (208)
- CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults (2005) (206)
- Antisense Research and Application (1998) (204)
- Enhanced Dendritic Cell Maturation by TNF-α or Cytidine-Phosphate-Guanosine DNA Drives T Cell Activation In Vitro and Therapeutic Anti-Tumor Immune Responses In Vivo1 (2000) (203)
- Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. (2006) (202)
- Induction of Systemic TH1-Like Innate Immunity in Normal Volunteers Following Subcutaneous but Not Intravenous Administration of CPG 7909, a Synthetic B-Class CpG Oligodeoxynucleotide TLR9 Agonist (2004) (198)
- CpG DNA rescue of murine B lymphoma cells from anti-IgM-induced growth arrest and programmed cell death is associated with increased expression of c-myc and bcl-xL. (1996) (197)
- Immune effects and mechanisms of action of CpG motifs. (2000) (188)
- Modification of antisense phosphodiester oligodeoxynucleotides by a 5' cholesteryl moiety increases cellular association and improves efficacy. (1993) (181)
- CpG still rocks! Update on an accidental drug. (2012) (179)
- CpG oligodeoxynucleotides can circumvent the Th2 polarization of neonatal responses to vaccines but may fail to fully redirect Th2 responses established by neonatal priming. (1999) (179)
- Synthetic oligodeoxynucleotides containing CpG motifs enhance immunogenicity of a peptide malaria vaccine in Aotus monkeys. (1999) (172)
- Inhibitory oligonucleotides specifically block effects of stimulatory CpG oligonucleotides in B cells (2002) (172)
- PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8⁺ T cells induced by melanoma vaccines. (2013) (169)
- Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2001) (168)
- New Generation Vaccine Induces Effective Melanoma-Specific CD8+ T Cells in the Circulation but Not in the Tumor Site1 (2006) (164)
- Enhancing vaccines with immune stimulatory CpG DNA. (2001) (161)
- CpG Are Efficient Adjuvants for Specific CTL Induction Against Tumor Antigen-Derived Peptide (2002) (159)
- Mechanisms and applications of immune stimulatory CpG oligodeoxynucleotides. (1999) (157)
- Oligodeoxynucleotide CpG 7909 Delivered as Intravenous Infusion Demonstrates Immunologic Modulation in Patients With Previously Treated Non-Hodgkin Lymphoma (2006) (153)
- Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. (2008) (152)
- Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. (2005) (152)
- CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens (2001) (152)
- Role of Mitogen-Activated Protein Kinases in CpG DNA-Mediated IL-10 and IL-12 Production: Central Role of Extracellular Signal-Regulated Kinase in the Negative Feedback Loop of the CpG DNA-Mediated Th1 Response1 (2002) (152)
- Endogenous retroviruses: potential etiologic agents in autoimmunity (1992) (151)
- CpG Oligodeoxynucleotide Enhances Tumor Response to Radiation (2004) (150)
- Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll‐like receptor 9 dependent T helper type 2 biased immune stimulation (2004) (148)
- CpG oligodeoxynucleotides do not require TH1 cytokines to prevent eosinophilic airway inflammation in a murine model of asthma. (1999) (147)
- CpG DNA Induces Maturation of Dendritic Cells with Distinct Effects on Nascent and Recycling MHC-II Antigen-Processing Mechanisms (2000) (143)
- CpG oligodeoxynucleotides potentiate the antitumor effects of chemotherapy or tumor resection in an orthotopic murine model of rhabdomyosarcoma. (2003) (141)
- CpG DNA Rescue from Anti-IgM-Induced WEHI-231 B Lymphoma Apoptosis via Modulation of IκBα and IκBβ and Sustained Activation of Nuclear Factor-κB/c-Rel (1998) (140)
- Causing a commotion in the blood: immunotherapy progresses from bacteria to bacterial DNA. (2000) (138)
- Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA. (1996) (137)
- An innate immune defense mechanism based on the recognition of CpG motifs in microbial DNA. (1996) (135)
- Mechanism of action of CpG DNA. (2000) (133)
- Immunostimulatory CpG oligodeoxynucleotides enhance the immune response to vaccine strategies involving granulocyte-macrophage colony-stimulating factor. (1998) (132)
- TLR9 Is Required for Protective Innate Immunity in Gram-Negative Bacterial Pneumonia: Role of Dendritic Cells (2007) (123)
- CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation. (2001) (122)
- The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokines and Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to Rhesus Macaques (2005) (121)
- Applied antisense oligonucleotide technology (1998) (121)
- CpG DNA is an effective oral adjuvant to protein antigens in mice. (2000) (120)
- Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 (2007) (120)
- CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma. (2003) (120)
- Phosphorothioate oligodeoxynucleotides: antisense or anti-protein? (1995) (117)
- Phase I Trial of Toll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non–Hodgkin's Lymphoma (2007) (116)
- CpG DNA: A pathogenic factor in systemic lupus erythematosus? (1995) (116)
- CpG Oligodeoxynucleotides Stimulate Protective Innate Immunity against Pulmonary Klebsiella Infection1 (2004) (113)
- Immunization With Analog Peptide in Combination With CpG and Montanide Expands Tumor Antigen-specific CD8+ T Cells in Melanoma Patients (2008) (109)
- Cyclosporin A enhances IL-12 production by CpG motifs in bacterial DNA and synthetic oligodeoxynucleotides. (1998) (109)
- Bacterial DNA and CpG–Containing Oligodeoxynucleotides Activate Cutaneous Dendritic Cells and Induce IL–12 Production: Implications for the Augmentation of Th1 Responses (1999) (107)
- Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse (2009) (105)
- Antiinfective applications of toll-like receptor 9 agonists. (2007) (99)
- Oligodeoxynucleotide modifications determine the magnitude of B cell stimulation by CpG motifs. (1996) (97)
- Mechanisms and therapeutic applications of immune stimulatory cpG DNA. (1999) (95)
- Dendritic cells from HIV-1 infected individuals are less responsive to toll-like receptor (TLR) ligands. (2007) (95)
- Modulating responsiveness of human TLR7 and 8 to small molecule ligands with T‐rich phosphorothiate oligodeoxynucleotides (2006) (92)
- Lactoferrin Binds CpG-Containing Oligonucleotides and Inhibits Their Immunostimulatory Effects on Human B Cells1 (2001) (92)
- NIH conference. Systemic lupus erythematosus. (1991) (92)
- Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. (2006) (91)
- Uptake of oligodeoxyribonucleotides by lymphoid cells is heterogeneous and inducible. (1991) (91)
- Distinct CpG oligonucleotide sequences activate human γ δ T cells via interferon‐α/‐β (2001) (91)
- A role for Toll in autoimmunity (2002) (91)
- Lipid-derived nanoparticles for immunostimulatory RNA adjuvant delivery (2012) (91)
- CpG Oligodeoxynucleotide and Montanide ISA 51 Adjuvant Combination Enhanced the Protective Efficacy of a Subunit Malaria Vaccine (2004) (90)
- Reduction of antigen expression from DNA vaccines by coadministered oligodeoxynucleotides. (1998) (90)
- Bacterial DNA-induced NK cell IFN-gamma production is dependent on macrophage secretion of IL-12. (1997) (90)
- APC Stimulated by CpG Oligodeoxynucleotide Enhance Activation of MHC Class I-Restricted T Cells1 (2000) (89)
- Negative control region at the 5' end of murine leukemia virus long terminal repeats (1989) (89)
- Comparative analysis of murine marrow-derived dendritic cells generated by Flt3L or GM-CSF/IL-4 and matured with immune stimulatory agents on the in vivo induction of antileukemia responses. (2002) (89)
- CpG oligodeoxynucleotides down-regulate macrophage class II MHC antigen processing. (1999) (89)
- A role for endogenous retroviral sequences in the regulation of lymphocyte activation. (1989) (87)
- CpG DNA rescues B cells from apoptosis by activating NFkappaB and preventing mitochondrial membrane potential disruption via a chloroquine-sensitive pathway. (1999) (87)
- Can immunization precipitate connective tissue disease? Report of five cases of systemic lupus erythematosus and review of the literature. (1999) (86)
- Bacterial DNA or oligonucleotides containing unmethylated CpG motifs can minimize lipopolysaccharide-induced inflammation in the lower respiratory tract through an IL-12-dependent pathway. (1999) (86)
- Clinical evaluation of safety and immunogenicity of PADRE-cytomegalovirus (CMV) and tetanus-CMV fusion peptide vaccines with or without PF03512676 adjuvant. (2012) (86)
- Induction and Regulation of Th1-Inducing Cytokines by Bacterial DNA, Lipopolysaccharide, and Heat-Inactivated Bacteria (1999) (85)
- Direct Immunologic activities of CpG DNA and implications for gene therapy (1999) (84)
- Now I know my CpGs. (2001) (83)
- Monocytes are required for optimum in vitro stimulation of bovine peripheral blood mononuclear cells by non-methylated CpG motifs. (2002) (83)
- TLR agonists regulate alloresponses and uncover a critical role for donor APCs in allogeneic bone marrow rejection. (2008) (83)
- Activation of Plasmacytoid Dendritic Cells with TLR9 Agonists Initiates Invariant NKT Cell-Mediated Cross-Talk with Myeloid Dendritic Cells1 (2006) (81)
- CpG-A-Induced Monocyte IFN-γ-Inducible Protein-10 Production Is Regulated by Plasmacytoid Dendritic Cell-Derived IFN-α1 (2003) (80)
- Synthetic unmethylated cytosine-phosphate-guanosine oligodeoxynucleotides are potent stimulators of antileukemia responses in naive and bone marrow transplant recipients. (2001) (79)
- Theoretical and Experimental Approaches to Generalized Autoimmunity (1990) (78)
- Retroviruses and autoimmunity. (1990) (78)
- Toll-Like Receptor 9 Regulates the Lung Macrophage Phenotype and Host Immunity in Murine Pneumonia Caused by Legionella pneumophila (2008) (76)
- A novel class of immune-stimulatory CpG oligodeoxynucleotides unifies high potency in type I interferon induction with preferred structural properties. (2010) (74)
- Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-α production through activation of NF-κB (2001) (74)
- C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. (2004) (72)
- Stage-specific oligonucleotide uptake in murine bone marrow B-cell precursors. (1994) (70)
- Exon skipping therapy for Duchenne muscular dystrophy. (2015) (69)
- Highly immunostimulatory CpG-free oligodeoxynucleotides for activation of human leukocytes. (2002) (68)
- Convergence of CpG DNA- and BCR-mediated signals at the c-Jun N-terminal kinase and NF-kappaB activation pathways: regulation by mitogen-activated protein kinases. (2003) (68)
- Deoxycytidyl-Deoxyguanosine Oligonucleotide Classes A, B, and C Induce Distinct Cytokine Gene Expression Patterns in Rhesus Monkey Peripheral Blood Mononuclear Cells and Distinct Alpha Interferon Responses in TLR9-Expressing Rhesus Monkey Plasmacytoid Dendritic Cells (2005) (67)
- Immunostimulatory CpG Oligodeoxynucleotide Confers Protection in a Murine Model of Infection with Burkholderia pseudomallei (2004) (66)
- Phagocytic antigen processing and effects of microbial products on antigen processing and T‐cell responses (1999) (65)
- From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. (2001) (65)
- A combination of Flt3 ligand cDNA and CpG ODN as nasal adjuvant elicits NALT dendritic cells for prolonged mucosal immunity. (2008) (64)
- Induction of CD8 T-Cell-Specific Systemic and Mucosal Immunity against Herpes Simplex Virus with CpG-Peptide Complexes (2002) (57)
- From A to Z on CpG. (2002) (56)
- Impact of class A, B and C CpG‐oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus‐1 infected individuals (2007) (56)
- Interleukin-10 functions in vitro and in vivo to inhibit bacterial DNA-induced secretion of interleukin-12. (1997) (55)
- CpG oligodeoxynucleotides stimulate IFN-γ-inducible protein-10 production in human B cells (2004) (54)
- NIH conference. Angioimmunoblastic lymphadenopathy with dysproteinemia. (1988) (54)
- Stimulation via Toll‐like receptor 9 reduces Cryptococcus neoformans‐induced pulmonary inflammation in an IL‐12‐dependent manner (2005) (53)
- Analysis of thymic endogenous retroviral expression in murine lupus. Genetic and immune studies. (1990) (52)
- Abstract CT144: Intratumoral toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab can reverse resistance to PD-1 inhibition in a phase Ib trial in subjects with advanced melanoma (2018) (52)
- CpG DNA: Trigger of Sepsis, Mediator of Protection, or Both? (2003) (51)
- CpG-DNA protects against a lethal orthopoxvirus infection in a murine model. (2005) (51)
- Synergy between CpG- or non-CpG DNA and specific antigen for B cell activation. (2003) (51)
- Paradoxical enhancement of CD8 T cell‐dependent anti‐tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine (2007) (49)
- Heterogeneous expression and coordinate regulation of endogenous retroviral sequences in human peripheral blood mononuclear cells. (1992) (49)
- CpG oligodeoxynucleotide enhances immunity against blood-stage malaria infection in mice parenterally immunized with a yeast-expressed 19 kDa carboxyl-terminal fragment of Plasmodium yoelii merozoite surface protein-1 (MSP1(19)) formulated in oil-based Montanides. (2003) (49)
- Modulation of CpG oligodeoxynucleotide-mediated immune stimulation by locked nucleic acid (LNA). (2004) (48)
- Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation (1996) (47)
- Adjuvant effects of CpG oligodeoxynucleotides on responses against T‐independent type 2 antigens (2001) (47)
- Antibody Repertoire Development in Fetal and Neonatal Piglets. IX. Three Pathogen-Associated Molecular Patterns Act Synergistically to Allow Germfree Piglets to Respond to Type 2 Thymus-Independent and Thymus-Dependent Antigens1 (2005) (45)
- CpG DNA: a novel immunomodulator. (1999) (44)
- Safety, Pharmacokinetics and Immune Effects in Normal Volunteers of CPG 10101 (ACTILON™), an Investigational Synthetic Toll-like Receptor 9 Agonist (2007) (44)
- Role of endogenous retroviruses in autoimmune diseases. (1994) (44)
- CpG DNA induces cyclooxygenase-2 expression and prostaglandin production. (2001) (43)
- A CpG Oligonucleotide Can Protect Mice from a Low Aerosol Challenge Dose of Burkholderia mallei (2006) (43)
- Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells (2004) (43)
- Direct immunologic activities of CpG DNA and implications for gene therapy. (1999) (43)
- Unmethylated CpG‐containing oligodeoxynucleotides inhibit apoptosis in WEHI 231 B lymphocytes induced by several agents: evidence for blockade of apoptosis at a distal signalling step (1997) (43)
- Biodegradable microspheres containing group B Streptococcus vaccine: immune response in mice. (2001) (42)
- The toll of too much TLR7. (2007) (42)
- Innate immune responses induced by classes of CpG oligodeoxynucleotides in ovine lymph node and blood mononuclear cells. (2007) (41)
- CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. (2004) (41)
- High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists1 (2006) (41)
- Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. (2008) (40)
- P-chirality-dependent immune activation by phosphorothioate CpG oligodeoxynucleotides. (2003) (40)
- Administration of a phosphorothioate oligonucleotide antisense to murine endogenous retroviral MCF env causes immune effects in vivo in a sequence-specific manner. (1993) (40)
- Whole blood cultures to assess the immunostimulatory activities of CpG oligodeoxynucleotides. (2001) (38)
- CpG-A-induced monocyte IFN-gamma-inducible protein-10 production is regulated by plasmacytoid dendritic cell-derived IFN-alpha. (2003) (38)
- Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer. (2006) (37)
- Retroviruses and Their Roles in Chronic Inflammatory Diseases and Autoimmunity (1995) (35)
- Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma (2021) (35)
- Biodistribution and metabolism of immunostimulatory oligodeoxynucleotide CPG 7909 in mouse and rat tissues following subcutaneous administration. (2005) (35)
- CpG oligodeoxynucleotides augment the murine immune response to the Yersinia pestis F1-V vaccine in bubonic and pneumonic models of plague. (2009) (34)
- Stimulation of innate immune responses by CpG oligodeoxynucleotide in newborn lambs can reduce bovine herpesvirus-1 shedding. (2006) (34)
- Distinct CpG oligonucleotide sequences activate human gamma delta T cells via interferon-alpha/-beta. (2001) (34)
- High prevalence of arthropathy in HTLV-I carriers on a Japanese island. (1996) (34)
- Antibody Opsonization of a TLR9 Agonist–Containing Virus-like Particle Enhances In Situ Immunization (2020) (33)
- Toll-free vaccines? (2007) (33)
- High Mobility Group B1 Protein Suppresses the Human Plasmacytoid Dendritic Cell Response to TLR9 Agonists (2006) (32)
- Chronic ethanol ingestion by mice increases expression of CD80 and CD86 by activated macrophages. (2004) (32)
- Immunopharmacology of CpG Oligodeoxynucleotides and Ribavirin (2004) (32)
- Type I interferon is the primary regulator of inducible Ly-6C expression on T cells. (2001) (31)
- Structure–Activity Relationship Studies on the Immune Stimulatory Effects of Base‐Modified CpG Toll‐Like Receptor 9 Agonists (2006) (31)
- Nonspecific suppression of [3H]thymidine incorporation by "control" oligonucleotides. (1992) (31)
- Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses. (2009) (31)
- Oligonucleotides with novel, cationic backbone substituents: aminoethylphosphonates. (1994) (31)
- Is RNAi dead? (2011) (30)
- CpG DNA rescue from anti-IgM-induced WEHI-231 B lymphoma apoptosis via modulation of I kappa B alpha and I kappa B beta and sustained activation of nuclear factor-kappa B/c-Rel. (1998) (29)
- Inhibitory oligonucleotides block the induction of AP-1 transcription factor by stimulatory CpG oligonucleotides in B cells. (2003) (29)
- Combining vaccination and postexposure CpG therapy provides optimal protection against lethal sepsis in a biodefense model of human melioidosis. (2011) (29)
- Immunostimulatory CpG oligonucleotides enhance the immune response of anti-idiotype vaccine that mimics carcinoembryonic antigen (2003) (29)
- Multiple endogenous xenotropic and mink cell focus-forming murine leukemia virus-related transcripts are induced by polyclonal immune activators (1988) (28)
- Immune effects and therapeutic applications of CpG motifs in bacterial DNA. (2000) (28)
- Oral Pretreatment of Mice with CpG DNA Reduces Susceptibility to Oral or Intraperitoneal Challenge with Virulent Listeria monocytogenes (2003) (27)
- Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma. (2006) (26)
- CpG oligonucleotides enhance the tumor antigen-specific immune response of an anti-idiotype antibody-based vaccine strategy in CEA transgenic mice (2006) (26)
- Lipopolysaccharide and CpG DNA synergize for tumor necrosis factor-alpha production through activation of NF-kappaB. (2001) (25)
- Immunostimulatory effects of three classes of CpG oligodeoxynucleotides on PBMC from HCV chronic carriers (2008) (24)
- Dendritic cells pulsed or fused with AML cellular antigen provide comparable in vivo antitumor protective responses. (2006) (24)
- NK cells activated in vivo by bacterial DNA control the intracellular growth of Francisella tularensis LVS. (2009) (23)
- Activation of Innate Immunity in Healthy Macaca mulatta Macaques by a Single Subcutaneous Dose of GMP CpG 7909: Safety Data and Interferon-Inducible Protein-10 Kinetics for Humans and Macaques (2007) (23)
- TLR9 and DNA 'feel' RAGE (2007) (22)
- Antitumor mechanisms of oligodeoxynucleotides with CpG and polyG motifs in murine prostate cancer cells: decrease of NF-kappaB and AP-1 binding activities and induction of apoptosis. (2002) (22)
- Expression of an endogenous retroviral transcript is associated with murine lupus. (1989) (22)
- Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune‐modulatory activity (2004) (22)
- Association of murine lupus and thymic full-length endogenous retroviral expression maps to a bone marrow stem cell. (1991) (21)
- AIMing 2 defend against intracellular pathogens (2010) (21)
- A possible cause of joint destruction in septic arthritis (1999) (19)
- Thrombotic thrombocytopenic purpura developing during pregnancy in a C2-deficient patient with a history of systemic lupus erythematosus. (1985) (19)
- Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression. (2008) (19)
- Minding the Cs and Gs. (2000) (19)
- DNA of Th 1 Responses by Immunostimulatory Role for Dendritic Cells in the Augmentation CpG-Containing Oligodeoxynucleotides : A Activation of Cutaneous Dendritic Cells by Udey and (1998) (19)
- Increased expression of novel full-length endogenous mink cell focus-forming-related transcripts in autoimmune mouse strains. (1988) (18)
- O85 Durable responses in anti-PD-1 refractory melanoma following intratumoral injection of a toll-like receptor 9 (TLR9) agonist, CMP-001, in combination with pembrolizumab (2020) (18)
- Combination of a new TLR9 agonist immunomodulator (CpG 7909) and paclitaxel for treatment of metastatic Lewis Lung Carcinoma (LLC). (2004) (18)
- Accumulation of glutathione disulfide mediates NF-kappaB activation during immune stimulation with CpG DNA. (2002) (17)
- Immunostimulatory potential of silencing RNAs can be mediated by a non-uridine-rich toll-like receptor 7 motif. (2011) (17)
- Positive T cell co-stimulation by TLR7/8 ligands is dependent on the cellular environment. (2011) (16)
- Oligonucleotide uptake in human hematopoietic cells is increased in leukemia and is related to cellular activation. (1996) (16)
- Signal transduction induced by immunostimulatory CpG DNA (2009) (16)
- Enhancing antisense efficacy with multimers and multi-targeting oligonucleotides (MTOs) using cleavable linkers (2015) (16)
- Inhibition of T4 polynucleotide kinase activity by phosphorothioate and chimeric oligodeoxynucleotides. (1994) (15)
- Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy (2010) (15)
- Enhanced Antibody Responses Elicited by a CpG Adjuvant Do Not Improve the Protective Effect of an Aldrithiol-2-Inactivated Simian Immunodeficiency Virus Therapeutic AIDS Vaccine (2009) (14)
- Identification of an oligodeoxynucleotide sequence motif that specifically inhibits phosphorylation by protein tyrosine kinases. (1997) (14)
- Induction of autoantibody production but not autoimmune disease in HEL transgenic mice vaccinated with HEL in combination with CpG or control oligodeoxynucleotides. (2004) (13)
- On the quality control of antisense oligonucleotides. (1996) (13)
- CD14+ cells are required for IL-12 response in bovine blood mononuclear cells activated with Toll-like receptor (TLR) 7 and TLR8 ligands. (2008) (13)
- Endogenous secretion of IL-4 maintains growth and Thy-1 expression of a transformed B cell clone. (1993) (13)
- Bacterial DNA does not increase serum corticosterone concentration or prevent increases induced by other stimuli. (2001) (12)
- Interruption of a transforming growth factor alpha autocrine loop in Caco-2 cells by antisense oligodeoxynucleotides. (1995) (12)
- 304 Intratumoral injection of CMP-001, a toll-like receptor 9 (TLR9) agonist, in combination with pembrolizumab reversed programmed death receptor 1 (PD-1) blockade resistance in advanced melanoma (2020) (11)
- CpG ODN As a Th1 Immune Enhancer for Prophylactic and Therapeutic Vaccines (2006) (11)
- AIMing 2 Detect Foreign DNA (2009) (11)
- B cells express Ly-6C in a Th1 but not Th2 cytokine environment. (2002) (11)
- Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. (2010) (10)
- The Toll of Cathepsin K Deficiency (2008) (10)
- Interleukin-12- and Gamma Interferon-Dependent Protection against Malaria Conferred by CpG Oligodeoxynucleotide in Mice (2002) (10)
- Applications of antisense oligodeoxynucleotides in immunology and autoimmunity research (1992) (10)
- Systemic innate immune responses following intrapulmonary delivery of CpG oligodeoxynucleotides in sheep. (2007) (10)
- Targeting LDL Cholesterol With LNA (2012) (10)
- TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune). (2004) (9)
- CpG oligonucleotides as immune adjuvants. (2000) (8)
- Immune Stimulation by Oligonucleotides (2021) (8)
- Early development of the Toll-like receptor 9 agonist, PF-3512676, for the treatment of patients with advanced cancers (2009) (7)
- Erratum: CPG oligodeoxyribonucleotides rescue mature spleen B cells from spontaneous apoptosis and promote cell cycle entry (Journal of Immunology (1998) 160 (5898-5906)) (1999) (7)
- The CpG motif: implications for clinical immunology. (1998) (7)
- Stimulation of Toll‐Like Receptor 9 for Enhancing Vaccination (2007) (7)
- Regulatory T Cells + CD 25 + Induce the Generation of CD 4 Activated by CpG Oligodeoxynucleotides Human Plasmacytoid Dendritic Cells (2004) (7)
- Mechanisms and Therapeutic Applications of Immune Modulatory Oligodeoxynucleotide and Oligoribonucleotide Ligands for Toll-Like Receptors (2007) (7)
- Molecular aspects of systemic lupus erythematosus: murine endogenous retroviral expression. (1992) (7)
- Rescue of B cells from apoptosis by immune stimulatory CpG DNA (2009) (7)
- Protection of Mice from Lethal Vaccinia Virus Infection by Vaccinia Virus Protein Subunits with a CpG Adjuvant (2017) (6)
- TLR9-targeted CpG immunostimulatory treatment of metastatic melanoma: A phase II trial with CpG 7909 (ProMune) (2004) (6)
- Enhance the Efficacy of Monoclonal Antibody Therapy of Lymphoma Immunostimulatory Oligodeoxynucleotides Containing CpG Motifs (1997) (6)
- DNA-based immune enhancers. (2000) (6)
- Abstract 1417: Combination cancer immunotherapy using checkpoint blockade and intratumoral virus-like particles containing CpG ODN (2016) (5)
- PD3-1-6: PF-3512676 (CPG 7909), a toll-like receptor 9 agonist-status of development for non-small cell lung cancer (NSCLC) (2007) (5)
- TLR 8-Dependent Immune Responses Stimulating Sequence-Specific Identification of RNA Sequence Motifs (2008) (5)
- Immune Effects of Bacterial DNA and Their Possible Role in the Pathogenesis of Lupus (1999) (5)
- ANTISENSE AND NUCLEIC ACID-BASED THERAPEUTICS: THE NEXT MILLENNIUM (1999) (5)
- Microenvironment and Immunology PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen – Speci fi c CD 8 þ T Cells Induced by Melanoma Vaccines (2014) (4)
- Immunostimulatory CpG motifs and DNA vaccines. (2000) (4)
- Potential use of CpG ODN for cancer immunotherapy (2006) (4)
- Approach to the use of antigen non-specific immunosuppression in systemic lupus erythematosus and other rheumatic autoimmune diseases (1988) (3)
- Abstract 2669: Antitumor activity of the CMP-001 (TLR9 agonist) alone or combined with immune modulators in syngeneic tumor models (2017) (3)
- Restriction fragment length polymorphism of T cell receptor alpha and beta chain genes in patients with ankylosing spondylitis. (1988) (3)
- Abstract CT032: CMP-001 demonstrates improved response in noninflamed anti-PD-1 refractory melanoma and response is associated with serum CXCL10 (2021) (3)
- 950 Final analysis: phase 1b study investigating intratumoral injection of toll-like receptor 9 agonist vidutolimod ± pembrolizumab in patients with PD-1 blockade–refractory melanoma (2021) (3)
- Mechanisms Recycling MHC-II Antigen-Processing Cells with Distinct Effects on Nascent and CpG DNA Induces Maturation of Dendritic (2000) (3)
- CpG oligonucleotide can protect mice from a low aerosol challenge dose of Burkholderia mallei , Infection and Immunity (2006) (3)
- Dendritic Cells Cell-Mediated Cross-Talk with Myeloid with TLR9 Agonists Initiates Invariant NKT Activation of Plasmacytoid Dendritic Cells (2006) (3)
- The ability of CpG oligonucleotides to protect mice against Francisella tularensis live vaccine strain but not fully virulent F. tularensis subspecies holarctica is reflected in cell-based assays. (2013) (3)
- Considerations in the Preclinical Assessment of the Safety of Antisense Oligonucleotides (2022) (3)
- Generation of Reactive Oxygen Species Leukocytes Through the pH-Dependent CpG Motifs in Bacterial DNA Activate (1998) (3)
- Timing of immunosuppression in the natural history of autoimmune diseases. (1992) (3)
- Phase Ib trial of the CpG-A Oligonucleotide CMP-001 combined with pembrolizumab (Pembro) in patients with advanced melanoma. (2016) (2)
- Class I-Restricted T Cells Oligodeoxynucleotide Enhance Activation of APC Stimulated by CpG and (2000) (2)
- Preferential nuclear compartmentalization of endogenous mink cell focus- forming-related retroviral transcripts (1990) (2)
- FP03.05 TLR9 Agonist CMP-001 Plus Atezolizumab +/- Radiation Therapy in Patients With PD-1 Blockade Resistant Advanced NSCLC (2021) (2)
- CpG oligonucleotides protect against Venezuelan equine encephalitis virus infection in a route-dependent manner. (2013) (2)
- 604 Intravenous CMP-001, a CpG-A Toll-like receptor 9 (TLR9) agonist delivered via a virus-like particle, causes tumor regression in syngeneic Hepa1–6 mouse models of hepatocellular carcinoma (2020) (2)
- Toward genetically targeted research and therapeutics. (1992) (2)
- A novel murine neuroblastoma vaccine strategy (2000) (2)
- Role of CpG motifs in immunostimulation and gene expression (2002) (1)
- Systematic Modulation of Immune Responses by CpG DNA (2001) (1)
- T Cells Induced by Melanoma Vaccines + CD 8 Specific − PD-1 and Tim-3 Regulate the Expansion of Tumor Antigen (2014) (1)
- The Toll-Like Receptor 7 (TLR7) Agonist, Imiquimod, and the TLR9 Agonist, CpG ODN, Induce Antiviral Cytokinesand Chemokines but Do Not Prevent Vaginal Transmission of Simian Immunodeficiency Virus When Applied Intravaginally to RhesusMacaques (2006) (1)
- Mind the gap! (2019) (1)
- How to Exclude Immunostimmulatory and Other Nonantisense Effects of Antisense Oligonucleotides (1999) (1)
- Applications of CpG Motifs from Bacterial DNA in Cancer Immunotherapy (2003) (1)
- CpG oligodeoxynucleotide (ODN) is a potent enhancer of fractionated radiotherapy. (2004) (1)
- Phase I Trial ofToll-Like Receptor 9 Agonist PF-3512676 with and Following Rituximab in Patients with Recurrent Indolent and Aggressive Non^Hodgkin’s Lymphoma (2007) (1)
- PD-1 and Tim-3 regulate the expansion of vaccine-induced tumor antigen-specific CD8+ T cells in patients with advanced melanoma (VAC3P.944) (2014) (1)
- Randomized Phase I-II Study of Vaccination With CpG 7909, Montanide ISA 720 and NY-ESO-1 Peptides for Patients With Stage III/IV Melanoma and NY-ESO-1+ Tumors: An Interim Analysis (2005) (1)
- CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma. (2021) (1)
- Receptor 9-Dependent Pathway Murine Dendritic Cells through a Toll-Like Human Plasmacytoid Dendritic Cells and Malaria Blood Stage Parasites Activate (2004) (1)
- Activation of skin-derived dendritic cells by CpG-containing oligodeoxynucleotides(ODN) with immunostimulatory activity (1998) (1)
- Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL). (2018) (1)
- Circulation but Not in the Tumor Site T Cells in the + Melanoma-Specific CD8 New Generation Vaccine Induces Effective (2015) (1)
- This information is current as Responses Established by Neonatal Priming Vaccines But May Fail to Fully Redirect Th 2 tothe Th 2 Polarization of Neonatal Responses CpG Oligodeoxynucleotides Can Circumvent (1999) (0)
- Enhancement of the Anthrax AVA Vaccine with CpG ODN's (2005) (0)
- A cell based vaccine strategy that enhances dendritic cell activation, migration and antigen uptake (2004) (0)
- La Rosa C et al (J Infect Dis 2012; 205:1294–304) (2013) (0)
- monocytogenes Listeria Intraperitoneal Challenge with Virulent Reduces Susceptibility to Oral or Oral Pretreatment of Mice with CpG DNA (2014) (0)
- CpG ODN enhances anti tumor effects of capecitabine in a murine model of established renal cell carcinoma (2003) (0)
- Pilot experiment for control of mosquito larvae in the field with an UV-treated preparation of bacillus thuringiensis var. israelensis (1980) (0)
- Immunostimulatory oligonucleotides class c semisoft. (2005) (0)
- Combination treatment of intratumoral vidutolimod (CMP-001), radiosurgery, nivolumab, and ipilimumab for metastatic colorectal carcinoma. (2023) (0)
- Expanded Prospects for Oligodeoxynucleotide Drugs (2003) (0)
- 845P Vidutolimod + pembrolizumab as 2L+ treatment in patients with anti–PD-1–refractory melanoma and adrenal insufficiency: Subgroup analyses of a phase Ib study (2022) (0)
- Activation of B cells by CpG Motifs in Bacterial DNA (2002) (0)
- The Journal Enters Its Third Year (1993) (0)
- Expression In Vivo and Resistance to CpG DNA Induces Sustained IL-12 (1998) (0)
- CpG DNA activates c-jun NH2-terminal kinase (1998) (0)
- Pneumonia: Role of Dendritic Cells Immunity in Gram-Negative Bacterial TLR9 Is Required for Protective Innate (2007) (0)
- A process for the preparation of nucleic acid constructs (1998) (0)
- 430 PLASMA LEVELS OF CD133+ MICROPARTICLES WITH DIFFERENT EXPRESSION OF ECTONUCLEOTIDASES INDICATE MAJOR HEPATIC RESECTIONS IN MICE AND HUMANS (2012) (0)
- Advancing Nucleic Acid Therapeutics by Setting Uniform Standards for Experimental Controls. (2019) (0)
- Retroviruses. Potential etiologic agents of autoimmunity (1992) (0)
- Use of non-methylated CpG dinucleotide in combination with aluminum as adjuvants (1998) (0)
- The Journal Continues to Develop (1991) (0)
- Compositions et procedes pour formulations a base d'oligonucleotides (2007) (0)
- Phase I study of immunization with the analogue peptide NY-ESO-1 157–165V in combination with CpG (PF-3512676) and Montanide ISA 720 in patients with stage III/IV melanoma (2008) (0)
- Hepatitis B Surface Antigen Immunity in Mice Immunized with Recombinant CpG DNA Is a Potent Enhancer of Specific (1998) (0)
- The Pendulum Swings Back (2001) (0)
- Production of preparations based on Bacillus thuringiensis var. israelensis with UV-inactivated spores for the biological control of mosquito larvae. (1980) (0)
- Immunostimulatory Effects on Human B Oligonucleotides and Inhibits Their Lactoferrin Binds CpG-Containing (2001) (0)
- Rigging Innate Immunity against the Flu. (2017) (0)
- New and old threats to human health (2001) (0)
- Oligodeoxynucleotides CpG Motifs in Bacterial DNA and Synthetic Cyclosporin A Enhances IL-12 Production by (1998) (0)
- Corrigendum: Toll-free vaccines? (2007) (0)
- 264 Strong Melan-A/MART-1 specific CD8+ T cell responses to peptide vaccination in young melanoma patients (2004) (0)
- Fractionated Radiotherapy Oligodeoxynucleotides Enhances Tumor Response to Targeting Toll-like Receptor 9 with CpG (2004) (0)
- Immunostimulatory oligonucleotides with combination motif with improved activity. (2002) (0)
- Antisense Editorial Office to Move (2001) (0)
- The Journal Reaches Its First Anniversary (1991) (0)
- Primary B Cells Identified CpG DNA Motif in Human Mechanism and Function of a Newly (1999) (0)
- Formulations compositions and methods for oligonucleotide (2007) (0)
- Absence of p 53 mutation in Japanese patients with rheumatoid arthritis : comment on the article (0)
- Th 1 Response Feedback Loop of the CpG DNA-Mediated Signal-Regulated Kinase in the Negative Production : Central Role of Extracellular CpG DNA-Mediated IL-10 and IL-12 Role of Mitogen-Activated Protein Kinases in Hong (2002) (0)
- Chapter 53 – CpG Oligodeoxynucleotides for Mucosal Vaccines (2005) (0)
- Antisense Is Here To Stay (1996) (0)
- CpG oligodeoxynucleotides (CpG ODN) improves survival after tumor resection in an orthotopic murine model of rhabdomyosarcoma (2005) (0)
- CpG Oligodeoxynucleotides and Their Potential Role in the Immunotherapy of Allergic Diseases (2002) (0)
- Potential of Antisense Technology in the Treatment of Immunological Disorders (1995) (0)
- MHC Class I-Restricted T Cells Oligodeoxynucleotide Enhance Activation of APC Stimulated by CpG (2000) (0)
- Polytherapie associant un anticorps anti-ctla-4 et un oligodesoxynucleotide synthetique a motif cpg destinee au traitement du cancer (2006) (0)
- The Journal Enters Its Second Year (1992) (0)
- Methods related to interferon induced inmuoestimuladores nucleic acids. (2000) (0)
- Combination motif-immunostimulatory oligonucleotides with improved effective (2002) (0)
- In Vivo CpG Administration Accelerates Graft-Versus-Host Disease (GVHD) Lethality by Toll-Like Receptor 9 (TLR9) Ligation of Host Antigen-Presenting Cells (APCs) and Promotes Allogeneic Bone Marrow (BM) Rejection by TLR9 Ligation of Donor APCs. (2006) (0)
- Phase 2 Study of Intratumoral Vidutolimod With Intravenous Cemiplimab in Patients With Locally Advanced or Metastatic Merkel Cell Carcinoma (CMP-001- 009) (2022) (0)
- Anti-tumor applications of activating toll-like receptor 9 with PF-3512676 (Formerly CPG 7909) (2006) (0)
- Uptake and Localization of Phosphodiester and Chimeric Oligodeoxynucleotides in Normal and Leukemic Primary Cells (2017) (0)
- Combination Lymphoma Immunotherapy Using Checkpoint Blockade and Intratumoral Virus-like Particles Containing CpG TLR9 Agonist (2016) (0)
- Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With Programmed Cell Death Protein 1 or Programmed Death-Ligand 1 Blockade–Resistant Advanced NSCLC (2022) (0)
- Antigen-Derived Peptide CTL Induction Against Tumor CpG Are Efficient Adjuvants for Specific (2002) (0)
- Combination motif immunostimulatory oligonucleotides having improved activity (2002) (0)
- Abstract LB107: Novel transcriptional signatures associated with antitumor activity in vidutolimod (vidu)-treated patients (pts) with anti-PD-1-refractory melanoma and non-small cell lung cancer (NSCLC) (2022) (0)
- Molecular targeting of toll-like receptor 9 with CpG oligodeoxynucleotides (ODN) for enhancement of tumor radioresponse (2004) (0)
- Clinical Development of Oligodeoxynucleotide TLR9 Agonists (2008) (0)
- Role of dose intensity of TLR9 agonist CpG ODN (CPG 7909) in the treatment of metastatic murine renal cell carcinoma. (2004) (0)
- Percent change in amount of IFN-α secreted by PBMC after 48 hr culture with rIFN-α (125 IU/ml) plu (2011) (0)
- in the Host or in the Tumor Itself Either Oligodeoxynucleotides Requires TLR9 Lymphoma Immunotherapy with CpG (2007) (0)
- CpG Motifs Distinct Effects of Oligodeoxynucleotides with Divergent Therapeutic and Immunologic (2013) (0)
- Enhancement of Anti-Tumor Efficacy of Paclitaxel by CpG ODN; TLR9 Agonist in Metastatic Murine Cancer Models (2004) (0)
- Five Years of Antisense—Moving Forward Into Our Sixth Year with an Expanded Editorial Focus (1996) (0)
- A New Editor at Oligonucleotides (2005) (0)
- the Human Plasmacytoid Dendritic Cell High Mobility Group B1 Protein Suppresses (2013) (0)
- Multimeric oiloncleotid connections (2012) (0)
- Through an IL-12-Dependent Pathway TractInflammation in the Lower Respiratory Minimize Lipopolysaccharide-Induced Containing Unmethylated CpG Motifs Can Bacterial DNA or Oligonucleotides (1999) (0)
- Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With PD-1/PD-L1 Blockade−Resistant Advanced Non−Small Cell Lung Cancer (2022) (0)
- A Special Issue: The Commercial Development of Nucleic Acids (2002) (0)
- Understanding the Challenges of Nucleic Acid Therapy (1997) (0)
- Macrophage Class II MHC Antigen CpG Oligodeoxynucleotides DownRegulate (1999) (0)
- CD14+ cells are required for TLR7/8 ligand-induced IL-12 and IFN-γ responses in bovine blood mononuclear cells (2009) (0)
- Nonspecific Immunomodulator Therapy (2005) (0)
- CANCER IMMUNOTHERAPIES AND VACCINES : PIPELINE ANALYSIS AND COMPETITIVE DYNAMICS An Interview with (2007) (0)
- Establishing Standards and Developing Concepts in a New Field (1991) (0)
- CPG DNA promotes the maturation and function of human monocyte-derived dendritic cells (modc) via indirect effects (2000) (0)
- The Manuscript Review Process (1993) (0)
- Cyclosporine A enhances IL-12 production by CpG DNA (1998) (0)
- Mind the gap! (2019) (0)
- From Molecular Science to the Treatment of Allergy (1999) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Arthur m. Krieg?
Arthur m. Krieg is affiliated with the following schools: